BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32499915)

  • 21. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.
    Ding YC; Yu W; Ma C; Wang Q; Huang CS; Huang T
    Int J Clin Exp Pathol; 2014; 7(11):8065-70. PubMed ID: 25550852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma.
    Zou W; Yang Z; Li D; Liu Z; Zou Q; Yuan Y
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):40-47. PubMed ID: 30531392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
    Yuan Y; Yang Z; Miao X; Li D; Liu Z; Zou Q
    Tumour Biol; 2015 Dec; 36(12):9961-8. PubMed ID: 26178481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
    Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
    Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer.
    Naka T; Kobayashi M; Ashida K; Toyota N; Kaneko T; Kaibara N
    Int J Oncol; 1998 May; 12(5):1111-6. PubMed ID: 9538137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
    Jeong J; Park YN; Park JS; Yoon DS; Chi HS; Kim BR
    Yonsei Med J; 2005 Aug; 46(4):519-25. PubMed ID: 16127777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
    Chen Y; Zhu H; Wang Y; Song Y; Zhang P; Wang Z; Gao J; Li Z; Du Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033818824314. PubMed ID: 30803373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.
    Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA
    Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma.
    Kuraishi Y; Uehara T; Kobayashi Y; Nakajima T; Watanabe T; Shimizu A; Ota H; Tanaka E
    Pathol Res Pract; 2019 Nov; 215(11):152623. PubMed ID: 31543221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
    Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
    Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
    Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
    Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review.
    Ding Y; Du Y
    Int J Surg; 2019 May; 65():32-38. PubMed ID: 30902754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.